Biocomo Co., Ltd. has developed an innovative vaccine vector technology that leverages the characteristics of the human parainfluenza virus. This technology combines the advantages of live viruses, such as high cellular adhesion, with the safety profile of inactivated viruses, resulting in a new type of vaccine that is both effective and safe. This vector technology is designed to enhance the immune response against various infectious diseases, showcasing Biocomo's commitment to advancing vaccine development.

In collaboration with Mie University and TFBS Bioscience Inc., Biocomo is actively working on a nasal spray vaccine targeting the Respiratory Syncytial Virus (RSV). This partnership aims to utilize the unique properties of their vaccine vector technology to create a more effective delivery method for vaccines, particularly for respiratory viruses. The focus on nasal spray formulations indicates a strategic approach to improve vaccine accessibility and patient compliance, further emphasizing the company's role in addressing public health challenges.

Japan

Research and development of biopharmaceuticals and bioproducts

Infectious Diseases

Biocomo Co., Ltd.

Biocomo Co., Ltd.

Company Details